BVT Bonus Zert SNW 31.12.2024/ DE000VM3PZX9 /
2024-11-15 8:56:01 AM | Chg.-0.44 | Bid10:00:37 PM | Ask10:00:37 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
139.10EUR | -0.32% | - Bid Size: - |
- Ask Size: - |
SANOFI SA INHABER ... | - EUR | 2024-12-31 | Call |
GlobeNewswire
09-02
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to ...
GlobeNewswire
08-26
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire
08-14
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
GlobeNewswire
08-13
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-12
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter ...
GlobeNewswire
08-08
Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free sur...
GlobeNewswire
08-06
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D ...
GlobeNewswire
08-01
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
07-31
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2...
GlobeNewswire
07-25
Press Release: Online availability of Sanofi’s half-year financial report for 2024
GlobeNewswire
07-25
Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
GlobeNewswire
07-24
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold...
GlobeNewswire
07-18
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, Accord...